ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Monday, 10 August 2015

Alzheimers Disease - Global Drug Forecast and Market Analysis to 2023 includes new market research report “PharmaPoint: Alzheimers Disease — Global Drug Forecast and Market Analysis to 2023 — Event-Driven Update” to its huge collection of research reports.

Alzheimers Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL), both for the patients and their caretakers. With rapidly accelerating worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area opportunity exists for the development of an effective pharmacologic approach.

Key Questions answered:-

- What are the preferred therapies for each country?

- The developmental pipeline consists of disease-modifying therapies (DMTs) that aim to prevent the disease in early- and presymptomatic patients. Which of these DMTs will attain high sales revenues during 2013–2023, and in which markets?

- Will amyloid-based therapies face adoption challenges in the market? What is the projected uptake of new passive immunotherapies and BACE inhibitors over the forecast period?

- How large an impact will Lundbecks LuAE-58054 and Forum/Mitsubishi Tanabes EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?

- What are the unique challenges in AD, and how will they affect the growth of the market globally?

Reasons to buy:-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most competitive pipelines.

- Develop business strategies by understanding the trends shaping and driving the AD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global AD market from 2013–2023.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents:

1 Table of Contents 8

1.1 List of Tables 15

1.2 List of Figures 21

2 Introduction 24

2.1 Catalyst 24

2.2 Related Reports 25

2.3 Upcoming Related Reports 25

3 Disease Overview 26

3.1 Etiology and Pathophysiology 26

3.1.1 Etiology 27

3.1.2 Pathophysiology 29

3.2 Disease Staging Systems 38

3.3 Symptoms 41

3.4 Prognosis 43

3.5 Quality of Life 43

4 Epidemiology 45

4.1 Disease Background 45

4.2 Risk Factors and Comorbidities 46

4.2.1 A family history of Alzheimers increases the risk of developing the disease by 7.5 times 47

4.2.2 The APOE

For More Information Kindly Contact:
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948


Post a Comment